Post Marketing Surveillance (PMS) Study of Ryzodeg™ (Insulin Degludec/Insulin Aspart) in Patients With Diabetes Mellitus in Routine Clinical Practice in India
A Multi-centre, Prospective, Open-label, Single-arm, Non-interventional, Post Marketing Surveillance (PMS) Study of Ryzodeg™ (Insulin Degludec/Insulin Aspart) to Evaluate Long Term Safety and Efficacy in Patients With Diabetes Mellitus in Routine Clinical Practice in India
Sponsor: Novo Nordisk A/S
A observational or N/A phase clinical study on Diabetes and Diabetes Mellitus, Type 1, this trial is completed. The trial is conducted by Novo Nordisk A/S and has accumulated 11 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Jun 2018 — Jan 2021 [monthly]
Completed
▶ Show 6 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Mar 2018 — Apr 2018 [monthly]
Completed NA
-
Sep 2017 — Mar 2018 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
May 2017 — Sep 2017 [monthly]
Active Not Recruiting NA
Status: Enrolling By Invitation → Active Not Recruiting
-
Feb 2017 — May 2017 [monthly]
Enrolling By Invitation NA
-
Jan 2017 — Feb 2017 [monthly]
Enrolling By Invitation NA
First recorded
Nov 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novo Nordisk A/S
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ahmedabad, India , Amritsar, India , Angamaly, India , Bangalore, India , Bilāspur, India , Chandigarh, India , Chennai, India , Coimbatore, India , Gandhinagar, India , Ghuma, India and 17 more locations